NCT02027155View on ClinicalTrials.gov

Phase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09

PHASE1TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Anesthesia
Interventions
DRUG

AR09 solution

moderate levels of sedation

DRUG

placebo

Sterile Saline, USP

Trial Locations (1)

27710

Duke Clinical Research Unit, Durham

Sponsors
All Listed Sponsors
lead

Arbor Pharmaceuticals, Inc.

INDUSTRY

NCT02027155 - Phase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09 | Biotech Hunter | Biotech Hunter